IMC-3C5
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Neoplasms
Conditions
Neoplasms
Trial Timeline
Mar 1, 2011 → Jul 1, 2014
NCT ID
NCT01288989About IMC-3C5
IMC-3C5 is a phase 1 stage product being developed by Eli Lilly for Neoplasms. The current trial status is completed. This product is registered under clinical trial identifier NCT01288989. Target conditions include Neoplasms.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01288989 | Phase 1 | Completed |
Competing Products
20 competing products in Neoplasms